These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15554597)

  • 1. Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice.
    Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
    Neth J Med; 2004; 62(7):229-34. PubMed ID: 15554597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
    Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
    Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
    Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
    J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Duvall WL; Blazing MA; Saxena S; Guyton JR
    J Cardiovasc Risk; 2002 Dec; 9(6):339-47. PubMed ID: 12478203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA
    Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
    Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
    J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective.
    Roze S; Ferrières J; Bruckert E; Van Ganse E; Chapman MJ; Liens D; Renaudin C
    Int J Clin Pract; 2007 Nov; 61(11):1805-11. PubMed ID: 17850322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of prolonged-release nicotinic acid in patients treated with statins as a secondary prevention and a persistently low HDL-cholesterol level in France].
    Paillard F; Mosnier M
    Ann Cardiol Angeiol (Paris); 2008 Apr; 57(2):121-6. PubMed ID: 18394585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidaemia in diabetic patients: time for a rethink.
    Shepherd J
    Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association between fibrate use, change in high-density lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up.
    Nichols GA; Koro CE; Chan W; Bowlin SJ; Sprecher DL
    Clin Ther; 2006 Feb; 28(2):243-50. PubMed ID: 16678645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan).
    Vogt A; Kassner U; Hostalek U; Steinhagen-Thiessen E
    Int J Clin Pract; 2007 Nov; 61(11):1914-21. PubMed ID: 17935550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia.
    Maccubbin D; Bays HE; Olsson AG; Elinoff V; Elis A; Mitchel Y; Sirah W; Betteridge A; Reyes R; Yu Q; Kuznetsova O; Sisk CM; Pasternak RC; Paolini JF
    Int J Clin Pract; 2008 Dec; 62(12):1959-70. PubMed ID: 19166443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy for the treatment of dyslipidemia.
    Streja D
    Curr Opin Investig Drugs; 2004 Mar; 5(3):306-12. PubMed ID: 15083597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH
    Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Ahmed MH
    J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
    Alagona P
    Am J Manag Care; 2009 Mar; 15(3 Suppl):S65-73. PubMed ID: 19355805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.